A4研究中自认同非西班牙裔黑人与白人参与者淀粉样蛋白PET差异
该研究分析A4研究筛查通过并接受淀粉样蛋白PET的3689名非西班牙裔白人和144名非西班牙裔黑人认知正常参与者,发现黑人淀粉样蛋白阳性率及连续水平更低,该差异在APOE ε4组最明显,且黑人中非洲祖源比例越低淀粉样蛋白越高。
要点
- 自认同非西班牙裔黑人参与者淀粉样蛋白阳性率和连续水平均低于白人。
- 种族对淀粉样蛋白的影响在APOE ε4携带者中最强。
- 黑人参与者中非洲祖源比例越低,淀粉样蛋白水平越高。
核心结论
- 通过A4研究初始筛选标准的自认同非西班牙裔黑人参与者淀粉样蛋白水平低于白人参与者。
- 应重视祖先多样化样本的阿尔茨海默病生物标志物研究及预防试验入选标准的公平性。
研究设计与样本
- 研究纳入通过A4研究初始筛选并接受淀粉样蛋白PET的3689名非西班牙裔白人和144名非西班牙裔黑人认知正常参与者。
- 采用逻辑回归和线性回归控制年龄、性别及APOE ε4和APOE ε2等位基因数分析种族对淀粉样蛋白PET的影响。
主要发现
- 非西班牙裔黑人参与者淀粉样蛋白阳性率更低且连续淀粉样蛋白水平更低。
- 种族对淀粉样蛋白的影响在APOE ε4组最强。
- 非西班牙裔黑人参与者中非洲祖源比例较低者淀粉样蛋白更高。
- 非西班牙裔黑人参与者未通过初始筛选的比例高于白人,提示A4 PET数据存在种族相关偏倚来源。
临床怎么用
- 解读认知正常人群淀粉样蛋白PET结果时应考虑种族和祖源背景差异。
- 设计阿尔茨海默病预防试验时应审慎评估入选标准对种族多样性的影响。
局限性
- 非西班牙裔黑人样本量远小于白人样本,可能影响统计效力。
- 非西班牙裔黑人参与者未通过初始筛选比例更高,提示存在种族相关选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether amyloid PET in cognitively normal (CN) individuals screened for the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) study differed across self-identified non-Hispanic White and Black (NHW and NHB) groups. METHODS: We examined 3,689 NHW and 144 NHB participants who passed initial screening for the A4 study and underwent amyloid PET. The effect of race on amyloid PET was examined using logistic (dichotomous groups) and linear (continuous values) regression controlling for age, sex, and number of APOE ε4 and APOE ε2 alleles. Associations between amyloid and genetically determined ancestry (reflecting African, South Asian, East Asian, American, and European populations) were tested within the NHB group. Potential interactions with APOE were assessed. RESULTS: NHB participants had lower rates of amyloid positivity and lower continuous amyloid levels compared to NHW participants. This race effect on amyloid was strongest in the APOE ε4 group. Within NHB participants, those with a lower percentage of African ancestry had higher amyloid. A greater proportion of NHB participants did not pass initial screening compared to NHW participants, suggesting potential sources of bias related to race in the A4 PET data. CONCLUSION: Reduced amyloid was observed in self-identified NHB participants who passed initial eligibility criteria for the A4 study. This work stresses the importance of investigating AD biomarkers in ancestrally diverse samples as well as the need for careful consideration regarding study eligibility criteria in AD prevention trials.
引用
- Deters KD, Napolioni V, Sperling RA, et al. Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study. Neurology. 2021. PMID: 33568538. doi:10.1212/WNL.0000000000011599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。